Pasithea Therapeutics annual shares outstanding
2021
2022
2023
2024
2025
Pasithea Therapeutics Shares Outstanding History (KTTA)
Pasithea Therapeutics reported 23.1M shares outstanding at the end of fiscal 2025.
View full Pasithea Therapeutics company overviewPasithea Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 23.1M | 21.7M | +1556.15% |
| 2024 | 2024-12-31 | 1.4M | 352,681 | +33.86% |
| 2023 | 2023-12-31 | 1.0M | −260,339 | −20.00% |
| 2022 | 2022-12-31 | 1.3M | 151,502.45 | +13.17% |
| 2021 | 2021-12-31 | 1.2M | — | — |
Pasithea Therapeutics quarterly shares outstanding
As of Dec 31, 2020
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 33.4M | 26.0M | +348.90% |
| Q1 2026 | 2026-03-31 | 24.9M | 22.2M | +821.90% |
| Q4 2025 | 2025-12-31 | 23.1M | 21.7M | +1556.15% |
| Q3 2025 | 2025-09-30 | 7.4M | 6.4M | +612.36% |
| Q2 2025 | 2025-06-30 | 7.4M | 6.4M | +612.93% |
| Q1 2025 | 2025-03-31 | 2.7M | 1.7M | +159.31% |
| Q4 2024 | 2024-12-31 | 1.4M | 352,681 | +33.86% |
| Q3 2024 | 2024-09-30 | 1.0M | 3,082.85 | +0.30% |
| Q2 2024 | 2024-06-30 | 1.0M | −263,089.35 | −20.13% |
| Q1 2024 | 2024-03-31 | 1.0M | −263,089 | −20.14% |
| Q4 2023 | 2023-12-31 | 1.0M | −260,339 | −20.00% |
| Q3 2023 | 2023-09-30 | 1.0M | −285,603.25 | −21.52% |
| Q2 2023 | 2023-06-30 | 1.3M | −27,764.05 | −2.08% |
| Q1 2023 | 2023-03-31 | 1.3M | 155,918.45 | +13.55% |
| Q4 2022 | 2022-12-31 | 1.3M | 151,502.45 | +13.17% |
| Q3 2022 | 2022-09-30 | 1.3M | 667,015.85 | +101.00% |
| Q2 2022 | 2022-06-30 | 1.3M | — | — |
| Q1 2022 | 2022-03-31 | 1.2M | — | — |
| Q4 2021 | 2021-12-31 | 1.2M | 776,962.3 | +208.05% |
| Q3 2021 | 2021-09-30 | 660,418.55 | — | — |
| As of Dec 31, 2020 | 2020-12-31 | 373,456.25 | — | — |
Pasithea Therapeutics Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Pasithea Therapeutics share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Pasithea Therapeutics used $0 to repurchase common stock in fy 2024. Across the latest 4 reported fiscal years, total share repurchases were $6.9M. The latest reported quarter showed $0 of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2024 | 2024-12-31 | $0 |
| 2023 | 2023-12-31 | $3.7M |
| 2022 | 2022-12-31 | $3.2M |
| 2021 | 2021-12-31 | $0 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Pasithea Therapeutics shares outstanding trends
Between the periods ended 2021-12-31 and 2025-12-31, Pasithea Therapeutics's shares outstanding moved from 1.2M to 23.1M, a change of 21.9M. The latest reported quarter, Q2 2026, shows 33.4M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pasithea Therapeutics source filings ↗